Lapis K, Jeney A, Divald A, Vajta G, Zalatnai A, Schaff Z
1. Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University, Budapest, Hungary.
Tokai J Exp Clin Med. 1986;11 Suppl:135-45.
The hepatopharmacological actions of Prostacyclin, 1-phosphate-4-amino 5-carboxamido-imidazole (AICA-P), Catergen, Silymarin and a thiazolidine compound were investigated by applications in in vitro and in vivo model systems. The usefulness of the in vitro system to screen for potential hepatoprotective agents and to investigate the molecular mechanism of these substances is shown. It was concluded that different patterns of hepatoprotective action were elaborated by the same drug depending on the model system used for testing. PGI2 and the thiazolidine compound showed remarkable protection in acute liver damage. However PGI2 circumvented only the CCl4 induced cellular injury, and was inactive in the galactosamine model system. The induction of cirrhosis could be modified by the simultaneous treatment with PGI2 or by the thiazolidine compound but the fully developed cirrhosis was not affected. On the contrary AICA-P and Silymarin treatment resulted in reduction of the amount of collagen in cirrhotic liver.
通过在体外和体内模型系统中的应用，研究了前列环素、1-磷酸-4-氨基-5-羧酰胺基咪唑（AICA-P）、卡特金、水飞蓟素和一种噻唑烷化合物的肝脏药理作用。结果表明，体外系统在筛选潜在的肝保护剂和研究这些物质的分子机制方面具有实用性。得出的结论是，同一药物根据用于测试的模型系统会表现出不同的肝保护作用模式。前列环素（PGI2）和噻唑烷化合物在急性肝损伤中显示出显著的保护作用。然而，PGI2仅能规避四氯化碳诱导的细胞损伤，在半乳糖胺模型系统中无活性。同时用PGI2或噻唑烷化合物治疗可改变肝硬化的诱导，但对完全发展的肝硬化无影响。相反，AICA-P和水飞蓟素治疗可减少肝硬化肝脏中的胶原含量。
